Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, they can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses.
One such company that might be well-positioned for future earnings growth is Amedisys, Inc. AMED. This firm, which is in the Medical – Outpatient and Home Healthcare industry, saw EPS growth of 42.6% last year, and is looking great for this year too.
In fact, the current growth estimate for this year calls for earnings-per-share growth of 40.9%. Furthermore, the long-term growth rate is currently an impressive 18.6%, suggesting pretty good prospects for the long haul.
Amedisys, Inc. Price and Consensus
And if this wasn’t enough, the stock has actually seen estimates rise over the past month for the current fiscal year by about 2.3%. Thanks to this rise in earnings estimates, AMED has a Zacks Rank #1 (Strong Buy) which further underscores the potential for outperformance in this company. You can see the complete list of today’s Zacks #1 Rank stocks here.
So, if you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider AMED. Not only does it have double-digit earnings growth prospects, but its impressive Zacks Rank suggests that analysts believe better days are ahead for AMED as well.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment